Acamprosate Calcium Tablet, Delayed Release
Product Images NDC 70771-1057

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Acamprosate Calcium (NDC 70771-1057). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (7e5f02ce F964 4059 Ae7e A862e17bfe9e 01)

Chemical structure of acamprosate calcium showing two molecular fragments each containing an acetylamide group and a sulfonate group, paired with a calcium ion (Ca2+). This depicts the molecular arrangement of the active ingredient acamprosate calcium.*

FDA Label Image

Figure (7e5f02ce F964 4059 Ae7e A862e17bfe9e 02)

Label for Acamprosate Calcium Delayed-release Tablets 333 mg, manufactured by Cadila Healthcare Ltd. The label includes the NDC 70771-1057 and states the package contains 180 tablets. It specifies that each delayed-release tablet contains 333 mg of acamprosate calcium, is Rx only, and includes storage and dispensing instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.